Background/Aims: Bleomycin is a clinically used anti-cancer drug that produces DNA breaks once inside of cells. However, bleomycin is a positively charged molecule and cannot get inside of cells by free diffusion. We previously reported that the cell surface negatively charged glycosaminoglycans (GAGs) may be involved in the cellular uptake of bleomycin. We also observed that a class of positively charged small molecules has Golgi localization once inside of the cells. We therefore hypothesized that bleomycin might perturb Golgi-operated GAG biosynthesis. Methods: We used stable isotope labeling coupled with LC/MS analysis of GAG disaccharides simultaneously from bleomycin-treated and non-treated cancer cells. To further understand the cytotoxicity of bleomycin and its relationship to GAGs, we used sodium chlorate to inhibit GAG sulfation and commercially available GAGs to compete for cell surface GAG/bleomycin interactions in seven cell lines including CHO745 defective in both heparan sulfate and chondroitin sulfate biosynthesis. Results: we discovered that heparan sulfate GAG was significantly undersulfated and the quantity and disaccharide compositions of GAGs were changed in bleomycin-treated cells in a concentration-and time-dependent manner. We revealed that bleomycin-induced cytotoxicity was directly related to cell surface GAGs. Conclusion: GAGs were targeted by bleomycin both at cell surface and at Golgi. Thus, GAGs might be the biological relevant molecules that might be related to the bleomycininduced fibrosis in certain cancer patients, a severe side effect with largely unknown molecular mechanism.
Heparan Sulfate and Chondroitin Sulfate Glycosaminoglycans Are Targeted by Bleomycin in Cancer Cells
have a Golgi localization once inside of the cells [36] . Based on the facts, we hypothesized that bleomycin might perturb Golgi-operated GAG biosynthesis. Bleomycin-induced changes in proteoglycans have been reported [37, 38] . However, direct effects of bleomycin on GAG structures and GAG-related signaling complex formation, and alterations in disaccharide composition and sulfation in GAGs have not been well documented due to technical difficulties in GAG structural analysis. Only the changes of disaccharide compositions of CS and dermatan sulfate (DS or CS-B) have been evaluated by fluorophore-assisted carbohydrate electrophoresis (FACE) in a bleomycin-treated rat model [39] . In current study, by using a novel stable isotope-labeling strategy, we showed that bleomycin reduced HS sulfation and altered CS quantity and disaccharide compositions in a concentration-and time-dependent manner based on LC-MS analysis. Therefore, bleomycin reduced HS sulfation in cancer cells with a molecular mechanism different from that of sodium chlorate and β-xylosides. Moreover, the novel GAG structural analysis methods and the GAG data provided in current study should be valuable in understanding the roles of GAGs played in bleomycin's cytotoxicity and bleomycin-induced lung fibrosis in future.
Materials and Methods
Cell culture and growth inhibition assay HCT116 and HT29 cells (Type culture collection of the Chinese Academy of Sciences, China) were maintained in McCoy's 5A media (Gibco, USA). H1299 and A549 cells (Type culture collection of the Chinese academy of sciences, China) were maintained in RPMI-1640 media (Hyclone, USA) as described previously [40] . Chinese hamster ovary (CHOK1, CHO 745, CHO 3.1) cells (gifts from Dr. Jeffrey D. Esko, University of California San Diego) were maintained in DMEM/F12 media (Hyclone, USA) supplemented with 5% heatinactivated FBS (Gibco, USA), 100 U/mL of penicillin, and 0.1 mg/mL of streptomycin (Gibco, USA) at 37°C with 5% CO 2 and 95% air in the incubator. All cells used were between 3 and 30 passages. DMSO (Solarbio, China) was used to dissolve bleomycin (Nippon Kayaku Co., Ltd., Japan) and the final concentration of DMSO in all cell-related experiments was 0.1%. For cell growth inhibition assay, HCT116, HT29, A549, H1299, CHO K1, CHO 745, CHO 3.1 cells were seeded in 96-well plates with 2000 cells in each well. After 24 h, cells were treated with serial concentrations of the bleomycin (10, 20, 40, 80 , and 160 μM) in 200 μL of complete media. After 48 h, each well was added 20 μL of 2 mg/mL resazurin (Sigma, USA) solution. After 16 h of incubation at 37°C, the fluorescent signal was monitored by using Spectramax M5 plate reader (Molecular Devices, USA) at 544 nm excitation wavelength and 595 nm emission wavelength. The relative fluorescence unit (RFU) generated from the assay was proportional to the number of living cells in each well.
The effects of sodium chlorate in cell culture media on the cytotoxicity induced by bleomycin Sulfation reactions can be inhibited when animal cells are treated with sodium chlorate [27] . In our experiment，HCT116, A549, and CHO 745 cells were seeded in 96-well plates with 2000 cells in each well. After 12 h, cells were incubated with different concentrations (0.016-10 mM) of sodium chlorate for 12 h in 150 μL of complete media. After 12 h, each well was added 50 μL of complete media with or without bleomycin (15 μM) for 48 h. After 48 h, each well was added 20 μL of resazurin (2 mg/mL dissolved in water, filtrate with 0.22 μm filter membrane). After 16 h of incubation at 37°C, the fluorescent signal was monitored by using Spectramax M5 plate reader at 544 nm excitation wavelength and 595 nm emission wave lengths.
Adding GAGs to cell cultural media to compete cell surface GAG and bleomycin binding to inhibit endocytosis thus cytotoxicity HCT116, A549, and CHO 745 cells were seeded in 96-well plates with 2000 cells in each well. After 24 h, cells were incubated with bleomycin (15 μM) in the presence or absence of varying concentrations of soluble GAG (0.15 μM, 1.5 μM, 15 μM) for 48 h in 200 μL of complete media. After 48 h, each well was added 20 μL of resazurin (2 mg/mL dissolved in water, filtrate with 0.22 μm filter membrane). After 16 h of incubation at 37°C, the fluorescent signal was monitored by using Spectramax M5 plate reader at 544 nm excitation wavelength and 595 nm emission wave lengths. GAGs were then extracted from the control and bleomycin treated cells by a previously published procedure [42] with minor modifications. The cells in each dish were first hydrolyzed by using 10 mL 100 mM NaOH. The cell lysates were collected in a 50 mL tube and incubated at 4°C overnight to release the GAG chains from core proteins by β-elimination reaction followed by adjusting the pH to 6.0 using 6 M HCl. Cell lysate (100 μL) from each group was collected and stored at -40°C. They were later used for protein quantification to calculate the GAG/protein ratio by using the BCA protein assay kit (Beyotime Biotechnology Co. Ltd., China). Protease (0.1 g/sample) (Tianshi corporation, China) was added to each 50 mL tube to digest GAG binding proteins by incubating at 37°C overnight. The protease was then inactivated by heating the tube in a 100°C water bath for 15 min. The supernatant was collected by centrifuging at room temperature at 4500 r/min for 15 min and the pH was adjusted to 6.0 by using 1 M HCl. Anion exchange resin (0.5 mL) was added into each tube and shook for 3 h. The supernatant was aspirated and the beads were washed three times with 3 mL 0.25 M NaCl, 0.01% Triton X-100, 20 mM NaAc pH 6.0 by re-suspension and centrifugation (5 min). The GAGs were pooled from the supernatants by three successive 500 µL 1.0 M NaCl, 0.01% Triton X-100, 20 mM NaAc pH 6.0 elution steps. The GAGs were precipitated by adding 100% ethanol to the supernatant with the final ethanol concentration of 80% for at least 2 h at 4°C. The precipitated GAGs were collected by centrifugation for 15 min at 4500 r/min and the supernatant was aspirated. The GAG pellet was washed with 0.5 mL of 75% ethanol. The GAGs in the dried pellet were dissolved in water in a siliconized tube and stored at 4 °C for further analysis.
Generating HS and CS disaccharide by enzymatic digestion
GAGs were divided into two parts, one for HS disaccharide analysis and the other for CS disaccharide analysis. For HS digestions, GAGs were incubated with 0.33 mU each of heparin lyase I, II, III (Biokangtai Pharmaceuticals, Inc., China) in a final volume of 50 μL 5 mM NH 4 Ac pH 7.0 in the presence of 0.125 mM CaCl 2 . To ensure the completion of the digestion, the digests were incubated at 37°C overnight after adding another round of the enzymes. For CS digestions, GAGs were incubated in 50 μL of digestion solution containing 5 mM ammonium acetate pH 7.0 and 1 mU chondroitinase ABC (Biokangtai Pharmaceuticals, Inc., China). Digestion was monitored by increased absorbance at 232 nm by using a Spectra MAX M2 platereading spectrophotometer with the temperature of the plate chamber set at 37°C [42] .
PMP labeling
Five μL of NH 3 ·H 2 O and 50 μL labeling reagents (either 0.5 M PMP or 0.5 M 2, 3,4, 5,6-deuterated PMP (D5PMP) dissolved in methanol) were added into the enzyme-digested samples and 0.5 M PMP (Sigma, USA) were added into the unsaturated HS and CS disaccharide standards (Sigma, USA). The labeling reaction was conducted for 1 h at 70°C. The NH 3 ·H 2 O was removed in a speed-vac. The extra PMP or D5PMP (synthesized by our laboratory) in the labeling reaction was extracted by using 1:2.5 volumes of chloroform three times. The PMP-and D5PMP-labeled products from the same amount of cellular proteins were mixed and ready for Liquid chromatography coupled mass spectrometry (LC/MS) analysis.
LC/MS analysis
The PMP-labeled commercial HS or CS disaccharide standards or the mixture of PMP-and D5PMP-labeled products were separated by using Agilent 1200 infinity capillary liquid chromatography system with a ZORBAX Stable Bond chromatogram column (5 μm, 0.5 x 250 mm). Solvent A was 10 mM ammonium acetate (pH 5.0); Solvent B was 100% acetonitrile. For HS analysis, the gradient used was 17-22% B in 60 min and 23% B for another 15 min and equilibrated with 17% B. For CS analysis, the gradient used was 13% B in 30 min, 20% B for 10 min and equilibrated with 13% B. The flow rate was 10 μL/min. The UV absorbance of PMP labeled products was monitored at 245 nm by using an online UV detector and the total Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry ion current (TIC) was collected using a Thermo LTQ-XL mass spectrometer operating in negative ion mode by scanning the m/z ranged from 300-2000. The mass chromatograms were processed by using Thermo Xcalibur software.
Statistical analysis
All statistical calculations were done using IBM SPSS Statistics 21. All data are represented as the mean ± S.D. Comparison between groups was made by Student's t-test to analyze the difference. P < 0.05 was considered to have statistical significance.
Results

Pair-wised comparison of the quantitative changes in each CS and HS disaccharide in bleomycin-treated vs. non-treated A549 and HCT116 cells
We hypothesized that bleomycin might perturb Golgi-operated GAG biosynthesis. To test, detailed GAG structural characterization from bleomycin-treated cell culture is required. We previously reported that IC 50 values for bleomycinin lung cancer A549 and colon cancer HCT116 cells are 17.5±2.4 and 13.4±1.7 μM, respectively [35] . Based on the published cytotoxicity study, a large proportion of cells will die after treating the cells with high concentration of bleomycin for an extended period of time [35] . To evaluate how bleomycin affected GAG biosynthesis and metabolism, we treated A549 and HCT116 cells with bleomycin either at high concentration for a short period of time (HCST: 80 μM 4 h) or low concentration for a long period of time (LCLT: 5 μM 48 h). Non-bleomycin treated cells were cultured at same time to serve as control. The final DMSO concentrations in all cell cultures were 0.1%. We then isolated GAGs from these cell cultures, respectively (See details in Materials and methods).
In GAG research field, disaccharide compositional analysis is used for GAG structural characterization. Of the different technologies available, LC/MS is the most robust method because of its higher sensitivity and accuracy. To facilitate quantitative comparison of GAG disaccharide compositions from different cell types, we have previously tagged the reducing end of enzyme-digested disaccharides with aniline-containing normal and stable isotopes [41] . Because different isotope tags have no effect on LC retention times but are discriminated by MS analysis, differentially isotope-tagged disaccharides can be compared simultaneously Table 1 . Molecular masses for PMP-or D5PMP-labeled HS and CS disaccharides detected in bleomycintreated or control A549 and HCT116 cells. The disaccharide structure code (DSC) [59] , the abbreviated chemical structure (ΔU = 4,5-unsaturated uronic acid), and the observed m/z values in negative ion mode for each enzymatically derived disaccharide are listed 
D2A0
, ΔUA-GlcNAc6S/D0A6) and di-sulfated HS disaccharides (ΔUA2S-GlcNS/D2S0) were deceased in the bleomycin-treated sample significantly, indicating bleomycin reduced the sulfation of both mono-and di-sulfated disaccharide in HS.
The CS and HS disaccharide compositions of bleomycin-treated or control A549 and HCT116 cells
Since we used a solvent gradient to separate each disaccharide by LC (See details in Materials and methods), the ion current intensity of the PMP-or D5PMP-labeled disaccharides increased with increased acetonitrile concentrations during the LC/MS analysis. Thus we used commercially available disaccharides to obtain the response factor for each disaccharide based on the method used in our previous publication [42] . The CS and HS disaccharide compositions were then calculated based on MS data and summarized in Table 2 .
First of all, CS and HS disaccharide compositions in A549 and HCT116 cells were different (Table 2) . Secondly, the percentage of non-sulfated HS disaccharide (D0A0) was greatly increased and all sulfated HS disaccharides were deceased in all bleomycin-treated GAG cells compared to the controls. In contrast, BLEOMYCIN treatment did not change the CS disaccharide compositions as drastically as that of HS (Table 2) . Thirdly, CS and HS compositions at two different bleomycin treatment conditions were different from each other ( Table 2 ). Interestingly, HS disaccharide D0A6 was present in LCLT culture of both bleomycin and control A549 cells but was undetectable in HCST culture of both bleomycin and control A549 cells (Table 2 ). In contrast, D0A6 was present in HCST culture of both bleomycin and control HCT116 cells but was undetectable in LCLT culture of both bleomycin and control HCT116 cells (Table 2) .
Bleomycin-induced changes in CS and HS disaccharides of A549 and HCT116 cells
The bleomycin-induced % changes in each HS or CS disaccharide compared to control in all samples were calculated (Table 3 ) and plotted in Fig. 2 , based on the disaccharide Table 2 . Disaccharide compositions of HS and CS from bleomycin-treated and untreated A549 and HCT116 cells (Percentage of each disaccharide in total disaccharides). Disaccharides from enzymatically digested HS and CS isolated from bleomycin-treated and untreated A549 and HCT116 cells were tagged with PMP or D5PMP, respectively. The 8 sets of PMP-or D5PMP-labeled samples were proportionally admixed to ensure equal cell-protein loading into 4 samples: A549 (LCLT: bleomycin + Control); A549 (HCST: bleomycin + Control); HCT116 (LCLT: bleomycin + Control); HCT116 (HCST: bleomycin + Control) before LC/MS analysis. The disaccharide compositions were calculated based on the MS signal intensity. Data are expressed as percentage of total disaccharide (mean +/-S.D., n = 3); bleomycin treatment conditions: LCLT (5 μM 48 h) and HCST (80 μM 4 h); ND, not detected; * P<0.05 vs control To clarify if GAG sulfation was required for the endocytosis-led cytotoxicity of bleomycin, we treated HCT116 , A549, and CHO 745 cells with the reversible sulfation inhibitor, sodium chlorate [48] (Fig. 3) . When concentrations were varied from 0.016 to 10 mM, sodium chlorate did not alter cell viability as shown in Fig. 3 . However, the cytotoxicity of bleomycin to A549 and HCT116 cells was significantly reduced by the addition of sodium chlorate (from 0.016 to 10 mM). In contrast, at comparable concentrations, the cytotoxicity of bleomycin to CHO 745 cells was significantly increased. Thus, sulfation was partially helped cellular uptake of bleomycin for both A549 and HCT116 cells whereas chlorate treatment had opposite effects on the GAG-deficient CHO 745 cells in the presence of bleomycin. Therefore, proper sulfated cell surface GAGs might be responsible for the uptake of bleomycin in A549 and HCT116 cells.
For an additional confirmation, we performed competitive binding assays by adding soluble GAGs, including CS-A, CS-B, CS-C, CS-D, CS-E, HS, and heparin to cell culture media to inhibit cell surface GAG/bleomycin binding. We used low, meddle, and high concentrations for each GAG with bleomycin or bleomycin alone for the inhibition experiment. Among the GAGs used, CS-A consists of mainly GlcA-GalNAc4S repeating disaccharides, CS-B contains both IdoA-GalNAc4S and GlcA-GalNAc4S as dominant repeating disaccharides, and CS-C consists of mainly GlcA-GalNAc6S repeating disaccharides. CS-D and CS-E are enriched in disulfated disaccharides, GlcA2S-GalNAc6S and GlcA-GalNAc4S6S, respectively. Heparan sulfate is from bovine kidney and heparin is from porcine mucosa. The data in Fig. 4 showed that high concentration of CS-A, CS-B, CS-C and Heparan almost reversed the cytotoxicity of bleomycin in HCT116 cells. Strikingly, all the GAGs at low, medium, and high concentrations reduced cytotoxicity of bleomycin in both HCT116 and A549 cells, especially A549 cells. In contrast, low, middle and high concentration of CS-A significantly increased cytotoxicity of bleomycin in GAG-deficient CHO 745 cells (Fig. 4) .
Discussion
The data in Fig. 2 , Tables 2 & 3 showed that HS was significantly undersulfated in both bleomycin-treated HCT116 and A549 cells and the HS and CS disaccharide compositions were very different in the bleomycin-treated and untreated HCT116 and A549 cells. Moreover, the Table 3 . Bleomycin-induced changes of specific HS and CS disaccharides in A549 and HCT116 cells compared to control. "↑" indicates the disaccharide was increased vs. that of control; "↓" indicates the disaccharide was decreased vs. that of control; ND, not detected. Bleomycin treatment conditions: LCLT (5 μM 48 h) and HCST (80 μM 4 h) 3   Table 3 . Bleomycin-induced changes of specific HS and CS disaccharides in A549 and HCT116 cells compared to control.
"↑" indicates the disaccharide was increased vs. that of control; "↓" indicates the disaccharide was decreased vs. that of control; ND, not detected. Bleomycin treatment conditions: LCLT (5 μM 48 h) and HCST (80 μM 4 h).
A549 HCT116
LCLT HCST LCLT HCST CS disaccharides Tables 2 & 3) . Thus, we concluded that BLEOMYCIN was a novel molecule that inhibited HS sulfation. Since bleomycin induces lung tissue-specific damage that leads to fibrosis in certain cancer patients and in different animal models [49] [50] [51] , our results would predict that the GAGs at lung epithelial cells might facilitate bleomycin uptake. Such experiment is currently conducted in our laboratory in a bleomycin-induced fibrosis mouse model.
Due to their template free biosynthesis, it is known that GAG structures are sensitive to drug treatment. We previously reported a 9-fold increase in GAG quantity after retinoic acid plus cAMP treatment of a F9 embryonal carcinoma cells by using a series of radio-active isotope involved assays [52] . To overcome the lacking of the access to radio-active isotope facilities, we used two radio-active material free assays to monitor the drug-induced changes in GAG structures in current studies. Moreover, the PMP-and D5PMP-labeling strategy allowed the quantity and disaccharide compositions in drug-treated and control cells to be compared simultaneously by LC/MS. (Fig. 2, Table 2 ). When coupled to reversed-phase LC, this assay permitted separation of nearly all known HS and CS disaccharides, including difficult to separate species bearing unsubstituted glucosamine residues, such as D2H0 and D0H6, as shown in Table 2 .
This LC/MS assay failed to detect the tri-sulfated HS disaccharide, D2S6, a relatively low abundant disaccharide but did detect a rarer disaccharide D2H0 in HS from different animal tissues and cell lines that was documented in the past (Fig. 6 in [53] ). Since the PMP-labeled D2S6 standard eluted and detected first by the LC-MS at lowest acetonitrile concentration, it required highest concentration to be detected compared to the rest of less sulfated and nonsulfated disaccharide standards. However, the D2S6 and the rest HS disaccharides in both heparin and porcine mucosa HS were detected and had correct disaccharide compositions by using the same assay (data not shown). Based on these facts, we concluded that the low abundant D2S6 in the A549 and HCT116 cells was below the detection limit of this assay. Nevertheless, this assay detected all possible CS and HS disaccharides except D2S6 when compared to all commercially available disaccharide standards (See details in Materials and methods).
We used 0.1% DMSO in all the control, at this concentration, DMSO was not toxic to both cell lines tested. However, LC/MS analysis (Table 2) showed that the control cells did not produce identical disaccharide compositions when exposed to 0.1% DMSO for short or longer periods of exposure (Table 3) , which suggested that 0.1% DMSO might affect GAG biosynthesis in both HCT116 and A549 cells.
Resistance to bleomycin and bleomycin-induced lung fibrosis are two major clinical concerns [30] . Fibrosis, a hallmark of clinical diseases that affects the normal functions of lung, liver, heart, or kidney, is defined as an abnormal accumulation of extracellular matrix components. HS and CS GAGs are key components in extracellular matrix. Lung fibrosis is induced in certain cancer patients treated with BLEOMYCIN with molecular mechanisms largely unknown. Bleomycin is the mostly used chemical in inducing lung fibrosis in animal models [8, 51] . Both FGF-2 and TGF-β signaling pathways play major roles in the fibrosis process and GAGs are co-regulators of both FGF-2 and TGF-β pathways [54, 55] . It is reported that a CS proteoglycan biglycan forms a complex with either transforming growth factor-β 1 or the transforming growth factor-β 1 type I receptor and to intensify the phosphorylation of Smad2/3, resulting in a lower expression of the transmembrane heparan sulfate proteoglycan, syndecan-4 [56] . Our results show that CS sulfation was not affected by bleomycin treatment as much as HS sulfation, which suggests that the balance between HS and CS was disrupted by the bleomycin in favor of TGF-β signaling during lung fibrosis. However, all most all cells make both HS and CS. Bleomycin only induces lung but not liver, heart, or kidney fibrosis in certain patients and in animals, which suggest the lung environment, especially the bleomycin-induced changes in HS and CS compositions and structures, might contribute to the reported observations. We are currently comparing the bleomycin-induced changes in HS and CS composition and structures isolated from lung, liver, heart, or kidney tissues using Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry
